Mail

HSDT - Helius Medical Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

7.45

+0.06 (+0.81%)

As of 10:47AM EST. Market open.

Stock chart is not supported by your current browser

Previous Close	7.39
Open	7.37
Bid	7.50 x 3100
Ask	7.50 x 1200
Day's Range	7.35 - 7.51
52 Week Range	6.72 - 13.20
Volume	9,490
Avg. Volume	94,867

Market Cap	192.336M
Beta (3Y Monthly)	-1.23
PE Ratio (TTM)	N/A
EPS (TTM)	-1.27
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	3.00

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire19 hours ago
Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
Business Wireyesterday
EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Helius Medical Technologies, Inc.; Investors are Encouraged to Contact the Firm
Rosen Law Firm, a global investor rights law firm, is continuing to investigate potential securities claims on behalf of shareholders of Helius Medical Technologies, Inc. resulting from allegations that Helius may have issued materially misleading business information to the investing public.
ACCESSWIRE7 days ago
HELIUS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Helius Medical Technologies, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helius Medical Technologies, Inc. ("Helius" ...
GlobeNewswire9 days ago
HELIUS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Helius Medical Technologies, Inc. to Contact the Firm
NEW YORK, Feb. 12, 2019 -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helius Medical Technologies, Inc..
GlobeNewswire10 days ago
Uptick Newswire Hosts Helius Medical Technologies, Inc. on the Stock Day Podcast to Discuss the Company’s Clearance in Canada and Expansion into The United States and Europe
Phoenix, Feb. 11th, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (the “Company”), a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly to discuss their clearance in Canada and share the progress of their expansion into the United States, Europe and Australia.
GlobeNewswire13 days ago
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. White Diamond Research published an article on January 22, 2019, which stated that Helius’ phase III drug trial “missed its primary effectiveness endpoint.” The report also stated that the Company “has redacted important trial info.” White Diamond research also questioned the veracity of the Company’s management team, alleging that the Company’s founders “have a history of questionable marketing practices,” and adding that the Company’s former CEO “is now a fugitive.” Based on this news, shares of Helius fell by more than 11.6% in the next two trading days.
PR Newswire14 days ago
Investor Alert: Kaplan Fox Investigates Helius Medical Technologies, Inc.
NEW YORK , Feb. 7, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Helius Medical Technologiues, Inc. ("Helius" ...
GlobeNewswire14 days ago
Bragar Eagel & Squire, P.C. is Investigating Helius Medical Technologies, Inc. (HSDT) on Behalf of Stockholders and Encourages HSDT Investors to Contact the Firm
NEW YORK, Feb. 07, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Helius Medical Technologies, Inc. (NASDAQ: HSDT). Our investigation.
GlobeNewswire14 days ago
Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2018 Financial Results on March 14, 2019
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2018 financial results will be released after the market closes on Thursday, March 14. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The webcast will be archived on the Events section of the Company’s investor relations website.
ACCESSWIRE17 days ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 28, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Helius Medical ...
GlobeNewswire21 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Helius Medical Technologies, Inc. (HSDT)
NEW YORK, Jan. 31, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Helius Medical.
GlobeNewswire21 days ago
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. White Diamond Research published an article on January 22, 2019, which stated that Helius’ phase III drug trial “missed its primary effectiveness endpoint.” The report also stated that the Company “has redacted important trial info.” White Diamond research also questioned the veracity of the Company’s management team, alleging that the Company’s founders “have a history of questionable marketing practices,” and adding that the Company’s former CEO “is now a fugitive.” Based on this news, shares of Helius fell by more than 11.6% in the next two trading days.
Business Wire22 days ago
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. White Diamond Research published an article on January 22, 2019, which stated that Helius’ phase III drug trial “missed its primary effectiveness endpoint.” The report also stated that the Company “has redacted important trial info.” White Diamond research also questioned the veracity of the Company’s management team, alleging that the Company’s founders “have a history of questionable marketing practices,” and adding that the Company’s former CEO “is now a fugitive.” Based on this news, shares of Helius fell by more than 11.6% in the next two trading days.
Business Wire23 days ago
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. White Diamond Research published an article on January 22, 2019, which stated that Helius’ phase III drug trial “missed its primary effectiveness endpoint.” The report also stated that the Company “has redacted important trial info.” White Diamond research also questioned the veracity of the Company’s management team, alleging that the Company’s founders “have a history of questionable marketing practices,” and adding that the Company’s former CEO “is now a fugitive.” Based on this news, shares of Helius fell by more than 11.6% in the next two trading days.
Business Wire23 days ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Helius Medical Technologies, Inc. – HSDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Helius Medical Technologies, Inc. resulting from allegations that Helius may have issued materially misleading business information to the investing public.
GlobeNewswire23 days ago
Helius Medical Technologies, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, Jan. 29, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Helius Medical.
GlobeNewswire27 days ago
Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS™ Device
During the substantive review phase of a request for De Novo classification and 510(k) clearance, FDA may request additional information in order to obtain information necessary for the agency to continue or complete its review and, in such instances, places its review on hold until the requested information is submitted.
GlobeNewswire2 months ago
Helius Medical Technologies, Inc. Announces Fourth Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has partnered with Kessler Institute for Rehabilitation and Kessler Foundation, New Jersey-based leaders in rehabilitation care and research, to implement its fourth Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™). PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and in the EU. PoNS is currently under review for US market clearance by the Food & Drug Administration (FDA) and EU clearance by the EU Notified Body.
GlobeNewswire2 months ago
Helius Medical Technologies, Inc. Announces Third Collaboration to Implement Clinical Experience Programs with PoNS™ Treatment in the United States
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, entered into an agreement in December 2018 to collaborate with Oregon Health & Science University (OHSU) in Portland, Oregon for launch of its third Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™). PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and in the EU. PoNS is currently under review for U.S. market clearance by the Food & Drug Administration (FDA) and EU market clearance by the EU Notified Body.
Simply Wall St.2 months ago
Read This Before Selling Helius Medical Technologies, Inc. (NASDAQ:HSDT) Shares
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...
GlobeNewswire2 months ago
Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS™ Device
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has submitted an application for a CE Mark, the receipt of which will allow the Company to market its Portable Neuromodulation Stimulator (PoNS™) in the European Union. PoNS is a licensed class II medical device in Canada and an investigational medical device in the U.S. and the European Union. “Helius is pleased to continue our exciting pace of progress with respect to our regulatory strategy with the submission of this important application during the fourth quarter,” said Philippe Deschamps, Helius’ Chief Executive Officer.
GlobeNewswire2 months ago
Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”) announced today that the underwriters of its previously announced public offering of 2,121,212 shares of Class A common stock which closed on November 19, 2018, have exercised their overallotment option to purchase an additional 318,182 shares of Class A common stock. The offering price to the public was $8.25 per share of Common Stock, and the underwriters purchased the shares from the Company pursuant to the Underwriting Agreement at a price of $7.755 per share. The Company has now sold a total of 2,439,394 shares of Class A common stock in connection with this offering, raising gross proceeds of approximately $20.1 million and estimates net proceeds of approximately $18.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.